• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Psychedelic Mushrooms May Help Treatment Resistant Depression
RESEARCH UPDATE

Psychedelic Mushrooms May Help Treatment Resistant Depression

June 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Bret A. Moore, PsyD, ABPP

Board-Certified Clinical Psychologist, San Antonio, TX

Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
(Carhart-Harris RL et al, Lancet Psychiatry, 2016; Epub ahead of print)

Short Description:

Mushrooms have been used as medicine for thousands of years, but it wasn’t until the 1950s that scientists took note of their potential healing properties. Psilocybin, a naturally occurring and psychedelic compound of the Psilocybe species of mushrooms, has garnered the most attention. 

Psilocybin is essentially a serotonin 2A agonist. Theoretically, this action should mediate depressive symptoms, but we don’t know for sure because no available antidepressants are direct agonists of this receptor. Researchers from the United Kingdom set out to see if this is indeed the case.

As part of an open-label feasibility study, six men and six women with moderate to severe treatment resistant depression (defined as two failed antidepressant trials) were administered a 10 mg oral dose of psilocybin and another 25 mg dose one week later. The goal of the first, lower dose was to test safety and tolerability; the second dose was the actual treatment. Researchers then monitored depressive symptoms with the Quick Inventory of Depressive Symptoms (QIDS) 1 week and 3 months post-treatment.

Overall, patients tolerated the psychedelic experience well. Short-term confusion or unclear thinking (n=9), nausea (n=4), and headaches (n=4) were the most common adverse effects. However, all patients experienced transient and mild to moderate anxiety shortly after taking the drug. It’s important to note that no patients dropped out of treatment because of side effects or the intensity associated with taking a psychedelic drug. Compared to baseline, scores were 11.8 and 9.2 points lower on the QIDS at 1 week and 3 months post-treatment, respectively.

TCPR’s Take: Exploring novel methods for battling treatment resistant depression is important since many patients don’t respond to antidepressants or psychotherapy. Ketamine (see TCPR, June 2016) and ultra-low dose buprenorphine (see TCPR, July/August 2016) are perfect examples. Both are “outside the box” treatments for severe depression and show tremendous promise. Psilocybin, a naturally occurring chemical found in certain psychedelic mushrooms, may have just joined their ranks. Although this is a very small, uncontrolled study, the initial results are promising and open the door for a more definitive, randomized clinical trial. 


                                                                                        


Addiction Treatment
KEYWORDS depressive_disorder research_updates
Bret a moore psyd abpp
Bret A. Moore, PsyD, ABPP

Extended-Release Guanfacine Improves ADHD Symptoms in Autism

More from this author
www.thecarlatreport.com
Issue Date: June 1, 2016
SUBSCRIBE NOW
Table Of Contents
Motivational Interviewing: Ten Tips
Using Motivational Interviewing in Your Practice
Psychedelic Mushrooms May Help Treatment Resistant Depression
Good News for Smoking Cessation Drugs: Not as Scary as Once Thought
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.